Gerhard Gründer, psychiatrist and psychotherapist, is a Professor at the Medical Faculty Mannheim at Heidelberg University. He heads the Department for Molecular Neuroimaging at the Central Institute for Mental Health in Mannheim. His main research interests include the neurobiology of mental disorders as well as molecular and clinical psychopharmacology. He uses functional imaging methods, in particular positron emission tomography (PET). His most recent interest is the clinical evaluation of psychedelic drugs in severe mental disorders, and he leads the largest academic-initiated clinical trial with a psychedelic (in treatment-resistant depression) ever done, the EPIsoDE trial.
Together with Henrik Jungaberle, Gerd Gründer is a CEO of OVID Health Systems, a clinical and drug development company that strives to improve Mental Health treatments. Since 2021, together with Andrea Jungaberle and Sergio Pérez, he leads the OVID Clinic Berlin – Germany’s first clinic for psychiatry and psychotherapy that implements psychedelic-augmented psychotherapies. |